Hendrik Witt1,2,3, Dorothee Gramatzki4, Bettina Hentschel5, Kristian W Pajtler1,2,3, Jörg Felsberg6,7, Gabriele Schackert8,9, Markus Löffler5, David Capper10,11,12, Felix Sahm10,11, Martin Sill1,2, Andreas von Deimling10,11, Marcel Kool1,2, Ulrich Herrlinger13, Manfred Westphal14, Torsten Pietsch15, Guido Reifenberger6,7, Stefan M Pfister1,2,3, Jörg C Tonn16, Michael Weller4. 1. Hopp-Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany. 2. Division of Pediatric Neuro-oncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany. 3. Department of Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany. 4. Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland. 5. Institute for Medical Informatics, Statistics, and Epidemiology, University of Leipzig, Leipzig, Germany. 6. Department of Neuropathology, Heinrich-Heine-University, Düsseldorf, Germany. 7. German Cancer Consortium(DKTK), partner site Essen/Düsseldorf, German Cancer Research Center(DKFZ), Heidelberg, Germany. 8. Department of Neurosurgery, Carl Gustav Carus University Hospital, Technical University of Dresden, Dresden, Germany. 9. Spine Center DWG Level I, Carl Gustav Carus University Hospital, Technical University of Dresden, Dresden, Germany. 10. Department of Neuropathology, Institute of Pathology, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. 11. Clinical Cooperation Unit Neuropathology, German Cancer Consortium(DKTK), German Cancer Research Center(DKFZ), Heidelberg, Germany. 12. Department of Neuropathology, Charité Universitätsmedizin Berlin and German Cancer Consortium(DKTK), partner site Berlin, Germany. 13. Department of Neurology, Division of Clinical Neuro-oncology, University of Bonn Medical Center, Bonn, Germany. 14. Department of Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 15. Department of Neuropathology, University of Bonn, Bonn, Germany. 16. Department of Neurosurgery, University of Munich LMU, Munich, Germany.
Abstract
Background: Ependymal tumors are glial tumors that commonly manifest in children and young adults. Their classification has remained entirely morphological until recently, and surgery and radiotherapy are the main treatment options, especially in adults. Here we sought to correlate DNA methylation profiles with clinical and pathological characteristics in the prospective cohort of the German Glioma Network. Methods: Tumors from 122 adult patients with myxopapillary ependymoma, ependymoma, anaplastic ependymoma, subependymoma, or RELA fusion-positive ependymoma classified according to the World Health Organization (WHO) 2016 were subjected to DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Molecular data were correlated with histologic features and clinical characteristics. Results: At a median follow-up of 86.7 months, only 22 patients experienced progression (18.0%) and 13 patients (10.7%) died. Each tumor could be assigned to one of the previously defined molecular ependymoma subgroups. All histologic subependymomas corresponded to subependymoma (SE) DNA methylation subgroups, but the reverse was not true: 19 histologic ependymomas (WHO grade II) were allocated to molecular SE groups. Similarly, all histological myxopapillary ependymomas were assigned to the molecularly defined spinal myxopapillary ependymoma (SP-MPE) class, but this molecular subgroup additionally included 15 WHO grade II ependymomas by histology. Overall, WHO grade II ependymomas distributed into 7 molecular subgroups. Conclusion: Most adult patients with ependymoma show a favorable prognosis. Molecular classification may provide diagnostic and prognostic information beyond histology and facilitate patient stratification in future clinical trials. The prognostic significance of a subependymoma or myxopapillary ependymoma DNA methylation phenotype without corresponding histology requires further study. Key Points: 1. Ependymoma diagnosed in adult patients most often shows a good prognosis. 2. Molecular classification can support diagnostic and prognostic information beyond histology.
Background: Ependymal tumors are glial tumors that commonly manifest in children and young adults. Their classification has remained entirely morphological until recently, and surgery and radiotherapy are the main treatment options, especially in adults. Here we sought to correlate DNA methylation profiles with clinical and pathological characteristics in the prospective cohort of the German Glioma Network. Methods: Tumors from 122 adult patients with myxopapillary ependymoma, ependymoma, anaplastic ependymoma, subependymoma, or RELA fusion-positive ependymoma classified according to the World Health Organization (WHO) 2016 were subjected to DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Molecular data were correlated with histologic features and clinical characteristics. Results: At a median follow-up of 86.7 months, only 22 patients experienced progression (18.0%) and 13 patients (10.7%) died. Each tumor could be assigned to one of the previously defined molecular ependymoma subgroups. All histologic subependymomas corresponded to subependymoma (SE) DNA methylation subgroups, but the reverse was not true: 19 histologic ependymomas (WHO grade II) were allocated to molecular SE groups. Similarly, all histological myxopapillary ependymomas were assigned to the molecularly defined spinal myxopapillary ependymoma (SP-MPE) class, but this molecular subgroup additionally included 15 WHO grade II ependymomas by histology. Overall, WHO grade II ependymomas distributed into 7 molecular subgroups. Conclusion: Most adult patients with ependymoma show a favorable prognosis. Molecular classification may provide diagnostic and prognostic information beyond histology and facilitate patient stratification in future clinical trials. The prognostic significance of a subependymoma or myxopapillary ependymoma DNA methylation phenotype without corresponding histology requires further study. Key Points: 1. Ependymoma diagnosed in adult patients most often shows a good prognosis. 2. Molecular classification can support diagnostic and prognostic information beyond histology.
Authors: Astrid Jeibmann; Rupert Egensperger; Klaus Kuchelmeister; Abolghassem Sepehrnia; Dietmar Stolke; Bernhard Bruns; Hansdetlef Wassmann; Heinrich Ebel; Werner Paulus; Martin Hasselblatt Journal: Histopathology Date: 2009-01 Impact factor: 5.087
Authors: Volker Hovestadt; David T W Jones; Simone Picelli; Wei Wang; Marcel Kool; Paul A Northcott; Marc Sultan; Katharina Stachurski; Marina Ryzhova; Hans-Jörg Warnatz; Meryem Ralser; Sonja Brun; Jens Bunt; Natalie Jäger; Kortine Kleinheinz; Serap Erkek; Ursula D Weber; Cynthia C Bartholomae; Christof von Kalle; Chris Lawerenz; Jürgen Eils; Jan Koster; Rogier Versteeg; Till Milde; Olaf Witt; Sabine Schmidt; Stephan Wolf; Torsten Pietsch; Stefan Rutkowski; Wolfram Scheurlen; Michael D Taylor; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; Arndt Borkhardt; Hans Lehrach; Robert J Wechsler-Reya; Roland Eils; Marie-Laure Yaspo; Pablo Landgraf; Andrey Korshunov; Marc Zapatka; Bernhard Radlwimmer; Stefan M Pfister; Peter Lichter Journal: Nature Date: 2014-05-18 Impact factor: 49.962
Authors: Martin J Aryee; Andrew E Jaffe; Hector Corrada-Bravo; Christine Ladd-Acosta; Andrew P Feinberg; Kasper D Hansen; Rafael A Irizarry Journal: Bioinformatics Date: 2014-01-28 Impact factor: 6.937
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister Journal: Cancer Cell Date: 2011-08-16 Impact factor: 31.743
Authors: Andrey Korshunov; Hendrik Witt; Thomas Hielscher; Axel Benner; Marc Remke; Marina Ryzhova; Till Milde; Sebastian Bender; Andrea Wittmann; Anna Schöttler; Andreas E Kulozik; Olaf Witt; Andreas von Deimling; Peter Lichter; Stefan Pfister Journal: J Clin Oncol Date: 2010-06-01 Impact factor: 44.544
Authors: Stephen C Mack; Sameer Agnihotri; Kelsey C Bertrand; Xin Wang; David J Shih; Hendrik Witt; Nadia Hill; Kory Zayne; Mark Barszczyk; Vijay Ramaswamy; Marc Remke; Yuan Thompson; Marina Ryzhova; Luca Massimi; Wieslawa Grajkowska; Boleslaw Lach; Nalin Gupta; William A Weiss; Abhijit Guha; Cynthia Hawkins; Sidney Croul; James T Rutka; Stefan M Pfister; Andrey Korshunov; Melike Pekmezci; Tarik Tihan; Joanna J Philips; Nada Jabado; Gelareh Zadeh; Michael D Taylor Journal: Clin Cancer Res Date: 2015-05-08 Impact factor: 12.531
Authors: Roberta Rudà; Guido Reifenberger; Didier Frappaz; Stefan M Pfister; Anne Laprie; Thomas Santarius; Patrick Roth; Joerg Christian Tonn; Riccardo Soffietti; Michael Weller; Elizabeth Cohen-Jonathan Moyal Journal: Neuro Oncol Date: 2018-03-27 Impact factor: 12.300
Authors: David Capper; David T W Jones; Martin Sill; Volker Hovestadt; Daniel Schrimpf; Dominik Sturm; Christian Koelsche; Felix Sahm; Lukas Chavez; David E Reuss; Annekathrin Kratz; Annika K Wefers; Kristin Huang; Kristian W Pajtler; Leonille Schweizer; Damian Stichel; Adriana Olar; Nils W Engel; Kerstin Lindenberg; Patrick N Harter; Anne K Braczynski; Karl H Plate; Hildegard Dohmen; Boyan K Garvalov; Roland Coras; Annett Hölsken; Ekkehard Hewer; Melanie Bewerunge-Hudler; Matthias Schick; Roger Fischer; Rudi Beschorner; Jens Schittenhelm; Ori Staszewski; Khalida Wani; Pascale Varlet; Melanie Pages; Petra Temming; Dietmar Lohmann; Florian Selt; Hendrik Witt; Till Milde; Olaf Witt; Eleonora Aronica; Felice Giangaspero; Elisabeth Rushing; Wolfram Scheurlen; Christoph Geisenberger; Fausto J Rodriguez; Albert Becker; Matthias Preusser; Christine Haberler; Rolf Bjerkvig; Jane Cryan; Michael Farrell; Martina Deckert; Jürgen Hench; Stephan Frank; Jonathan Serrano; Kasthuri Kannan; Aristotelis Tsirigos; Wolfgang Brück; Silvia Hofer; Stefanie Brehmer; Marcel Seiz-Rosenhagen; Daniel Hänggi; Volkmar Hans; Stephanie Rozsnoki; Jordan R Hansford; Patricia Kohlhof; Bjarne W Kristensen; Matt Lechner; Beatriz Lopes; Christian Mawrin; Ralf Ketter; Andreas Kulozik; Ziad Khatib; Frank Heppner; Arend Koch; Anne Jouvet; Catherine Keohane; Helmut Mühleisen; Wolf Mueller; Ute Pohl; Marco Prinz; Axel Benner; Marc Zapatka; Nicholas G Gottardo; Pablo Hernáiz Driever; Christof M Kramm; Hermann L Müller; Stefan Rutkowski; Katja von Hoff; Michael C Frühwald; Astrid Gnekow; Gudrun Fleischhack; Stephan Tippelt; Gabriele Calaminus; Camelia-Maria Monoranu; Arie Perry; Chris Jones; Thomas S Jacques; Bernhard Radlwimmer; Marco Gessi; Torsten Pietsch; Johannes Schramm; Gabriele Schackert; Manfred Westphal; Guido Reifenberger; Pieter Wesseling; Michael Weller; Vincent Peter Collins; Ingmar Blümcke; Martin Bendszus; Jürgen Debus; Annie Huang; Nada Jabado; Paul A Northcott; Werner Paulus; Amar Gajjar; Giles W Robinson; Michael D Taylor; Zane Jaunmuktane; Marina Ryzhova; Michael Platten; Andreas Unterberg; Wolfgang Wick; Matthias A Karajannis; Michel Mittelbronn; Till Acker; Christian Hartmann; Kenneth Aldape; Ulrich Schüller; Rolf Buslei; Peter Lichter; Marcel Kool; Christel Herold-Mende; David W Ellison; Martin Hasselblatt; Matija Snuderl; Sebastian Brandner; Andrey Korshunov; Andreas von Deimling; Stefan M Pfister Journal: Nature Date: 2018-03-14 Impact factor: 49.962
Authors: Volker Hovestadt; Marc Remke; Marcel Kool; Torsten Pietsch; Paul A Northcott; Roger Fischer; Florence M G Cavalli; Vijay Ramaswamy; Marc Zapatka; Guido Reifenberger; Stefan Rutkowski; Matthias Schick; Melanie Bewerunge-Hudler; Andrey Korshunov; Peter Lichter; Michael D Taylor; Stefan M Pfister; David T W Jones Journal: Acta Neuropathol Date: 2013-05-14 Impact factor: 17.088
Authors: Taciani de Almeida Magalhães; Kleiton Silva Borges; Graziella Ribeiro de Sousa; Silvia Regina Brandalise; Ana Luiza Seidinger; Carlos Alberto Scrideli; Sueli Mieko Oba-Shinjo; José Andrés Yunes; Luiz Gonzaga Tone Journal: Neurol Sci Date: 2019-11-14 Impact factor: 3.307
Authors: Michael Bockmayr; Kim Harnisch; Lara C Pohl; Leonille Schweizer; Theresa Mohme; Meik Körner; Malik Alawi; Abigail K Suwala; Mario M Dorostkar; Camelia M Monoranu; Martin Hasselblatt; Annika K Wefers; David Capper; Jürgen Hench; Stephan Frank; Timothy E Richardson; Ivy Tran; Elisa Liu; Matija Snuderl; Lara Engertsberger; Martin Benesch; Andreas von Deimling; Denise Obrecht; Martin Mynarek; Stefan Rutkowski; Markus Glatzel; Julia E Neumann; Ulrich Schüller Journal: Neuro Oncol Date: 2022-10-03 Impact factor: 13.029
Authors: Christian Thomas; Felix Thierfelder; Malte Träger; Patrick Soschinski; Michael Müther; Dominic Edelmann; Alexandra Förster; Carola Geiler; Hee-Yeong Kim; Katharina Filipski; Patrick N Harter; Jens Schittenhelm; Franziska Eckert; Georgios Ntoulias; Sven-Axel May; Walter Stummer; Julia Onken; Peter Vajkoczy; Ulrich Schüller; Frank L Heppner; David Capper; Arend Koch; David Kaul; Werner Paulus; Martin Hasselblatt; Leonille Schweizer Journal: Acta Neuropathol Date: 2021-03-23 Impact factor: 17.088
Authors: Felix Ehret; Markus Kufeld; Christoph Fürweger; Alfred Haidenberger; Paul Windisch; Carolin Senger; Melina Kord; Malte Träger; David Kaul; Christian Schichor; Jörg-Christian Tonn; Alexander Muacevic Journal: Front Oncol Date: 2021-04-29 Impact factor: 6.244
Authors: David W Ellison; Kenneth D Aldape; David Capper; Maryam Fouladi; Mark R Gilbert; Richard J Gilbertson; Cynthia Hawkins; Thomas E Merchant; Kristian Pajtler; Sriram Venneti; David N Louis Journal: Brain Pathol Date: 2020-06-23 Impact factor: 7.611